Advanced Colorectal Cancer Clinical Trial
Official title:
A Multicenter Phase II Clinical Study of Bevacizumab Combined With Biweekly XELOX/XELIRI Alternative First-line Treatment for Unresectable Advanced Colorectal Cancer
The objective is to investigate the efficacy and safety of two-weekly alternative regimen of Bevacizumab plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer.
XELOX is a commonly used chemotherapy regimen, and XELIRI has also been widely used in the second-line treatment. XELOX and XELIRI adopt the three-week regimen, and the single dose of oxaliplatin and irinotecan is large, which has a great impact on the gastrointestinal toxicity and blood toxicity of patients. Therefore, there is no lack of a two-week improved regimen with increased frequency and reduced single dose applied in clinical, so that it has good safety, exact efficacy and increase the drug delivery density. Based on the above, we should not only consider the efficiency of the three drugs, but also control the toxic reaction. The objective is to evaluate the efficacy and safety of two-weekly alternative regimen of Bevacizumab plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
| Recruiting |
NCT06200363 -
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT02923622 -
Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer
|
N/A | |
| Completed |
NCT01723969 -
Screening Platform for Clinical Trials in Advanced Colorectal Cancer
|
||
| Active, not recruiting |
NCT00309179 -
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03699111 -
Identification of New Patient Stratification Tools in MSS RAS mt mCRC
|
||
| Not yet recruiting |
NCT02826837 -
LEAC-102 for Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05077839 -
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC
|
Phase 2 | |
| Not yet recruiting |
NCT06369259 -
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00707889 -
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT01271166 -
Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT00386828 -
Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial
|
Phase 2 | |
| Recruiting |
NCT04764006 -
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
|
Phase 2 | |
| Active, not recruiting |
NCT04835324 -
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
|
||
| Active, not recruiting |
NCT02619435 -
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT01822444 -
ANGIOPREDICT. ICORG 12-16, V3
|
||
| Completed |
NCT00498407 -
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05731336 -
A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
|
||
| Active, not recruiting |
NCT04744831 -
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT03311750 -
Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
|
Phase 2 |